Frank M. Mason
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Frank M. Mason has a total of 304 co-authors. Here are the top co-authors by number of shared publications:
- Aguirre A. de Cubas
Medical University of South Carolina 1 Department of Pharmacology and Immunology Charleston, South Carolina
33 shared publications - Anusha Uprety
Medical University of South Carolina 1 Department of Pharmacology and Immunology Charleston, South Carolina
33 shared publications - Chandler Judd
Medical University of South Carolina 1 Department of Pharmacology and Immunology Charleston, South Carolina
33 shared publications - Emily D. Villella
Medical University of South Carolina 1 Department of Pharmacology and Immunology Charleston, South Carolina
33 shared publications - Jezabel Rodriguez-Blanco
Medical University of South Carolina 3 Darby Children’s Research Institute Charleston, South Carolina
33 shared publications - Keith D. Robertson
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
33 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S10. Immunoblot analysis of MCL1 expression to confirm MCL1 KO. KU80 was used as a loading control.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S10. Immunoblot analysis of MCL1 expression to confirm MCL1 KO. KU80 was used as a loading control.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S18 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S18. SETD2 WT and SETD2-deficient 786-O cells were treated with dideoxycytidine to deplete mitochondrial DNA (mtDNA). Cells were subsequently treated with DMSO or 100nM A-1331852 for 72 hours, and total DNA was isolated. mtDNA levels were quantified by qPCR. GAPDH was used as an endogenous reference.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S18 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S18. SETD2 WT and SETD2-deficient 786-O cells were treated with dideoxycytidine to deplete mitochondrial DNA (mtDNA). Cells were subsequently treated with DMSO or 100nM A-1331852 for 72 hours, and total DNA was isolated. mtDNA levels were quantified by qPCR. GAPDH was used as an endogenous reference.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S7. Pathways significantly enriched in SETD2 KO 786-O (red) and A498 (blue) cells relative to parental RCC cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S7. Pathways significantly enriched in SETD2 KO 786-O (red) and A498 (blue) cells relative to parental RCC cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S17 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S17. cGAS was deleted using CRISPR/Cas9 in SETD2 WT and SETD2-deficient 786-O cells. Cells were treated with DMSO or 100nM A-1331852 for 72 hours, and viability was assessed by Alamar Blue assay. Experiments were performed in triplicate.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S17 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S17. cGAS was deleted using CRISPR/Cas9 in SETD2 WT and SETD2-deficient 786-O cells. Cells were treated with DMSO or 100nM A-1331852 for 72 hours, and viability was assessed by Alamar Blue assay. Experiments were performed in triplicate.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S9. Pathways significantly enriched in SETD2 KO 786-O cells treated with 100nM A-1331852 relative to vehicle-treated controls.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S9. Pathways significantly enriched in SETD2 KO 786-O cells treated with 100nM A-1331852 relative to vehicle-treated controls.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Table S7. Differential expression analysis performed comparing NOXA-High to NOXA-Low ccRCCs in the TCGA dataset. Expression measured by RNAseq.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Table S7. Differential expression analysis performed comparing NOXA-High to NOXA-Low ccRCCs in the TCGA dataset. Expression measured by RNAseq.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Table S5. Differential expression analysis performed comparing SETD2-deficient to WT for A498 cells. Expression measured by RNAseq.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Table S5. Differential expression analysis performed comparing SETD2-deficient to WT for A498 cells. Expression measured by RNAseq.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S5. Immunoblot confirmation of SETD2 and H3K36me3 protein levels in SETD2 WT, SETD2 KO, and SETD2 KO+FLSETD2 786-O cells. Total Histone H3 and Actin were used as loading controls.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S5. Immunoblot confirmation of SETD2 and H3K36me3 protein levels in SETD2 WT, SETD2 KO, and SETD2 KO+FLSETD2 786-O cells. Total Histone H3 and Actin were used as loading controls.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S16 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S16. STING was deleted using CRISPR/Cas9 in SETD2 WT and SETD2-deficient 786-O cells. Cells were treated with DMSO or 100nM A-1331852 for 72 hours and harvested to assess inflammatory signaling and NOXA expression by immunoblot. Actin was used as a loading control.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S16 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S16. STING was deleted using CRISPR/Cas9 in SETD2 WT and SETD2-deficient 786-O cells. Cells were treated with DMSO or 100nM A-1331852 for 72 hours and harvested to assess inflammatory signaling and NOXA expression by immunoblot. Actin was used as a loading control.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S6. Heatmap visualization of unsupervised hierarchical clustering of the top most variably expressed genes. A498 (n = 2 per condition) and 786-O cells (n = 3 per condition) were analyzed.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Figure S6. Heatmap visualization of unsupervised hierarchical clustering of the top most variably expressed genes. A498 (n = 2 per condition) and 786-O cells (n = 3 per condition) were analyzed.